Expression of p16 protein in gallbladder carcinoma and its precancerous conditions.
OBJECTIVE
Adenocarcinoma of the gallbladder is a highly malignant neoplasm. p16 is a tumor suppressor gene protein, which is a cyclin-dependent kinase inhibitor that regulates the G1-S phase of the cell cycle. The purpose of the present study was to investigate the expression of p16 in gallbladder carcinoma and its precancerous conditions and to examine the relationship between p16 expression and clinicopathological parameters.


METHODS
Formalin-fixed, paraffin-embedded tissue sections from 20 cases of normal gallbladder, 20 cases of chronic cholecystitis, 20 cases of gallbladder adenoma, 20 cases of dysplasia, and 58 cases of adenocarcinoma were examined. The expression of p16 was evaluated by immunohistochemical analysis.


RESULTS
In normal gallbladder, no expression of p16 was found. In chronic cholecystitis, expression of p16 was not found. In gallbladder adenomas, expression of p16 was found in 20% (4/20). In low grade dyspalsias, expression of p16 was not found. In high grade dysplasias, p16 expression was present in 45.0% (9/20). In gallbladder adenocarcinomas, p16 expression was found in 27.6% (16/58). Expression of p16 correlated significantly with histologic grade (p < 0.05). No correlation was found between p16 expression and age, gender, tumor size, gross type, location, vascular invasion, lymph node metastasis, and TNM stage, respectively.


CONCLUSIONS
P16 protein overexpression is an early and relatively common event in carcinogenesis of gallbladder carcinoma. Expression of p16 protein is absent in normal or chronic cholecystitis. Expression of p16 may be an ancillary diagnostic marker of gallbladder carcinoma and its precancerous conditions.
Choi
Hye-Jeong
HJ
Department of Pathology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
Yun
Sung Su
SS
Kim
Hong Jin
HJ
Choi
Joon Hyuk
JH
D000236:Adenoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D002277:Carcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D002764:Cholecystitis / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16; D005260:Female; D005706:Gallbladder Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D011230:Precancerous Conditions / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
D015415:Biomarkers; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins